Eylea Injection contains Aflibercept, a recombinant fusion protein that acts as a VEGF inhibitor. It is administered intravitreal (directly into the eye) to treat retinal conditions that cause abnormal blood vessel growth and fluid leakage, leading to vision loss.
- Eylea is approved for managing:
- Wet Age-Related Macular Degeneration (AMD)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR)
- Macular Edema following Retinal Vein Occlusion (RVO)
- Retinopathy of Prematurity (ROP) in infants
It works by binding to VEGF-A and PlGF, preventing them from stimulating unwanted blood vessel formation. Treatment typically begins with monthly injections, followed by maintenance doses every 2 months, depending on the condition and response.
